Avances en el tratamiento de los niños y adolescentes con infección por HIV / Advances in the treatment of children and adolescents with HIV infection

El uso de antirretrovirales (ARV) en el embarazo, el parto y el recién nacido y la aplicación de tratamientos combinados en los niños se han asociado con una disminución del sida en pediatría y el aumento de la sobrevida. La introducción de los inhibidores de integrasa en una dosis diaria ha eliminado barreras para la adherencia, pero los medicamentos orales diarios continúan planteando problemas de privacidad y estigma. Las nuevas tecnologías de administración de los medicamentos y las nuevas drogas junto con la combinación de ARV y los anticuerpos ampliamente neutralizantes (bNAb), ofrecen un potencial de opciones futuras para el tratamiento pediátrico del HIV. Los bNAb son anticuerpos que pueden reconocer diferentes tipos de HIV, bloquear su entrada en las células sanas y ayudar a destruir las células ya infectadas, pueden administrarse por vía parenteral y constituyen un enfoque novedoso y seguro con potencial para el tratamiento y la prevención del HIV, incluida la transmisión vertical. En los lactantes que contraen HIV, los bNAb podrían ofrecer ventajas terapéuticas al reducir el reservorio del virus, mejorar la inmunidad adquirida y, en el futuro, proporcionar un camino hacia la cura funcional. Dentro de los ARV inyectables de acción prolongada, cabotegravir/ rilpivirina se ha incorporado en las guías internacionales de adultos y adolescentes tanto para el tratamiento como para la prevención. A medida que el tratamiento del HIV en adultos va evolucionando, es fundamental asegurar que los neonatos, lactantes, niños y adolescentes tengan acceso a las mejores opciones de tratamiento y prevención a lo largo de su vida (AU)

The use of antiretrovirals (ARVs) during pregnancy, delivery, and in the newborn and the use of combination therapy in children have been associated with a decrease in pediatric AIDS and increased survival. The introduction of once-daily integrase inhibitors has removed barriers to adherence, but daily oral medications continue to pose privacy and stigma issues. New drug delivery technologies and new drugs along with the combination of ARVs and broadly neutralizing antibodies (bNAbs) offer potential future options for pediatric HIV treatment. bNAbs are antibodies that can recognize different types of HIV, block their entry into healthy cells and help destroy already infected cells, can be delivered parenterally, and represent a novel and safe approach with potential for the treatment and prevention of HIV, including mother-to-child transmission. In infants who contract HIV, bNBAs could offer therapeutic advantages by reducing the viral reservoir, enhancing acquired immunity and, in the future, providing a pathway to a functional cure. Within the long-acting injectable ARVs, cabotegravir/rilpivirine has been incorporated into international guidelines for adults and adolescents for both treatment and prevention. As adult HIV treatment evolves, it is critical to ensure that newborns, infants, children and adolescents have access to the best treatment and prevention options throughout their lives (AU)

[Epidemiology, treatment and prognosis of HIV infection in 2024: A practical review]. / Epidemiología, tratamiento y pronóstico de la infección VIH en 2024: revisión práctica.

In recent years, the epidemiology and prognosis of HIV infection have undergone significant changes thanks to the recommendation of antiretroviral therapy (ART) for all infected persons, the development of more effective and better tolerated drugs, and preventive measures such as pre-exposure prophylaxis (PrEP). The evolution of ART, now with simple oral and injectable options, has also contributed to improvements in comprehensive HIV treatment and care. With early diagnosis and early initiation of ART, the life expectancy of people with HIV has reached the same as the general population. However, many people with HIV remain undiagnosed or are diagnosed late, and some population groups experience greater vulnerability, affecting individual and collective health. In this review we review the current epidemiology, treatment and prognosis of HIV infection.

Intervenciones psicológicas para mejorar la adherencia al tratamiento antirretroviral: Revisión sistemática y metaanálisis / Psychological interventions to improve adherence to antiretroviral treatment: Systematic review and meta-analysis

Resumen El VIH es una enfermedad crónica que afecta a los receptores CD4 del sistema inmunológico. El Tratamiento Antirretroviral (TARV) es vital para disminuir la carga viral, pero su éxito depende del grado de adherencia al mismo. El objetivo de este estudio fue revisar los factores asociados a la eficacia de las intervenciones psicológicas para incrementar la adherencia al TARV y agregar los hallazgos en estimaciones cuantitativas de su impacto en la adherencia. La revisión de la literatura fue realizada desde agosto de 2017 hasta abril de 2020 en PubMed, EBSCO y Springer Link, utilizando los siguientes criterios de elección de los estudios: (1) que estuvieran publicados en revistas indexadas con revisión por pares, (2) que fueran experimentales o cuasiexperimentales, (3) que emplearan técnicas para el incremento de la adherencia, (4) que estuvieran publicados en español o inglés, (5) que reportaran los estadísticos necesarios para el cálculo del tamaño de efecto. De los 15 estudios seleccionados (. total = 1669), se obtuvieron 38 tamaños del efecto. El cálculo de los tamaños de efecto individuales y global se realizó usando el programa Comprehensive Meta-Analysis (Biostat, 2011, v. 2.2.064). Todos los tamaños de efecto fueron calculados usando la diferencia estandarizada de medias y un modelo de efectos aleatorios. El tamaño de efecto global fue moderado (. = 0.56, . = 38, IC95 % = 0.39 - 0.72, . < .001), mostrando que las intervenciones fueron significativamente superiores al grupo de comparación. Debido a la alta heterogeneidad de los estudios (I. = 82.25), se analizaron 12 variables moderadoras, de las cuales 11 fueron significativas (. < .005). Los resultados del análisis de variables moderadoras indican un mayor efecto en el incremento de la adherencia al TARV en intervenciones con marcos teóricos basados en el apoyo social por pares y con metodologías adaptables a la vivencia cotidiana de la persona.

Abstract HIV is a chronic disease that affects the CD4 receptors of the immune system, so it is necessary for people with the virus to be under Antiretroviral Treatment (ART) to reduce the viral load in the body. The success of ART is related to adherence to treatment, understood as: the intake of antiretroviral drugs, follow-up of medical controls and implementation of healthy lifestyles. There are personal, social and health systems problems that prevent people from adhering to ART in an adequate way. This situation has become a public health problem because inappropriate taking of drugs often leads to drug resistance. In this way, it is necessary to implement effective psychological interventions aimed at increasing adherence to ART, to contribute to a better use of antiretrovirals and to the improvement of the quality of life of people with HIV. Accordingly, the objective was to review the factors associated with the efficacy of psychological interventions, to increase adherence to ART and to aggregate the findings in quantitative estimates of its impact on adherence. For this purpose, meta-analysis was used as a research technique that allows a quantitative analysis of results by calculating specific statistics. The literature search and review were carried out from August 2017 to May 2019 in the PubMed, Academic Search Complete (EBSCO Host) and Springer Link databases, for the identification of experimental studies that met the eligibility criteria (studies published in peer-reviewed indexed journals, experimental or quasi-experimental research, using techniques to increase adherence, published in Spanish and English and reporting the necessary statistics for effect size calculation). Of the 15 studies (total n = 1669) selected, 38 effect sizes were obtained. The calculation of the individual and global effect size was performed using the Comprehensive Meta-Analysis software (Biostat, 2011, v. 2.2.064). All the effect sizes were calculated using the standardized mean difference and a random effects model. To find out if individual effect sizes were homogeneous and therefore represent a similar measure of treatment efficacy, the Cochran Q homogeneity test was applied; based on this, the I. was calculated. Also, it was performed a publication bias calculation, the objective of which was to estimate the number of non-significant effect sizes that are required for a reduction of the global effect size to a smaller and non-significant one. The overall effect size was moderate (. = 0.56, . = 38, 95 % CI = 0.39 - 0.72, . < .001) and presented high heterogeneity (I. = 82.25). Twelve moderator variables were analyzed (year of publication, percentage of men, average age, measurement time, number of sessions / interactions, duration of sessions, total duration of intervention, economic remuneration for intervention, place where the intervention was carried out, type of intervention, intervention modality and adherence measurement), of which 11 were significant (all but intervention modality: individual vs. group therapy). The results suggest that the success of an intervention proposal to improve adherence to ART will be related to its ability to consider the components of the environment and the social situation in which the person with HIV develops, as well as their intrinsic characteristics in interaction with their context. Likewise, it is necessary to consider that the presence of adherence barriers should be treated specifically in young people and adults, as well as in men and women. Finally, it is more important to establish interventions aimed not only to increase adherence, but maintaining it, which is why it is considered necessary to propose studies aimed at maintaining adherence, as well as offering practical tools for people to make better decisions about their health.

Análisis de 23 pacientes con infección por VIH y Covid-19. Estudio descriptivo / Analysis of 23 patients with HIV infection and Covid-19. Descriptive study

Las características clínicas, el diagnóstico, el pronóstico, el tratamiento y la profilaxis de la infección por el coronavirus SARS-CoV-2 en los pacientes infectados por el VIH, son muy similares a los de la población general cuando estos se encuentran con supresión de la replicación viral con el tratamiento antirretroviral y tienen una cifra de linfocitos T CD4 + > de 200 células/uL. El tiempo medio de incubación es de 5 días (entre 2 y 14 días). En sujetos VIH positivos, cuánto mayor es la carga viral plasmática para VIH y el recuento de CD4 + es < 200 cél/uL, el tiempo que transcurre entre la infección por el coronavirus y la aparición de las manifestaciones clínicas es menor. En la población general, el 70-80% de individuos tienen una infección por SARS-CoV-2 leve/moderada, un 20-25% grave y un 5% muy grave que requiere internación en UTI. En los pacientes infectados por el VIH se desconoce esta proporción, aunque estudios preliminares consideran que las proporciones serían del 66%, 22% y 12%, respectivamente25. Se presenta una serie de 23 pacientes con coinfección SARS-CoV-2/VIH y se analizan las características epidemiológicas, clínicas y la evolución en relación con ambas infecciones

The clinical characteristics, diagnosis methods, medical prognosis, treatment alternatives and prophylaxis of coronavirus SARS-CoV-2 infection in HIV infected individuals are very similar in patients under HAART with undetectable viral load and CD4+ > than 200 cell/uL. The mean incubation time is of 5 days (range 2 to 14 days). In HIV-seropositive patients, with high viral load and CD4 < 200 cell/ uL, the time between infection for coronavirus and the onset of symptoms is minor. In the general population, 70% to 80% of individuals infected by SARS-CoV-2 develops a mild to moderate disease; 20% to 25% severe forms and 5% develops very severe clinical compromise that requieres intensive therapy unit income. In HIV-positive patients these percentages would be 66%, 22% y 12%, respectively25. Here we present a series of 23 HIV-seropositive patients coinfected by coronavirus SARS-CoV-2; we analyzed the epidemiology, clinical manifestations and the evolution related with both infections

Prevalencia de glucosa alterada en ayuno y dislipidemia entre pacientes mexicanos con VIH naïve a tratamiento antirretroviral.

BACKGROUND: Metabolic complications have become more relevant in the care of patients with HIV. However, little is known about the incidence and risk factors for these disorders among HIV-infected antiretroviral treatment naïve (ARTn) patients. OBJECTIVE: To recognize the prevalence of Impaired Fasting Glucose (IFG) and dyslipidemia among HIV-infected ARTn Mexican individuals and identify associated risk factors. METHOD: A retrospective study was conducted in HIV-1-infected ART-N patients, referred for attention to a general hospital in Mexico City, between 2009 and 2019. We collected information for anthropometric, clinical, biochemical and HIV status variables. RESULTS: We included 221 patients, 97% were males, mean age 30 years (interquartile range [IQR]: 25-38); median CD4 count was 250 cells/mm3 (IQR: 120.25-391) and median log10 HIV viral load was 4.69 HIV-1 RNA copies/ml (IQR: 3.64-5.25). Prevalence of IFG was 22.6% and was associated with overweight-obesity (odds ratio [OR]: 2.75; 95% confidence interval [95% CI]: 1.36-5.55; p-value < 0.05). Hypoalphalipoproteinemia was the most frequent dyslipidemia: 69.46%. An association between count CD4 < 250 and lower HDL cholesterol levels was found (OR: 3.23; 95CI%: 1.61-6.5; p-value < 0.05). CONCLUSIONS: IFG and dyslipidemia are highly prevalent among HIV-infected ART-naïve Mexican patients, therefore, screening for glucose and lipids abnormalities always should be considered among ARTn patients.

ANTECEDENTES: Las alteraciones metabólicas se han vuelto más relevantes en el cuidado de los pacientes con infección por el virus de la inmunodeficiencia humana (VIH). Existe poca información sobre estas alteraciones en pacientes naïve a tratamiento antirretroviral (nTAR). OBJETIVO: Identificar la prevalencia de glucosa alterada en ayuno y dislipidemia entre individuos mexicanos con VIH nTAR e identificar los factores asociados. MÉTODO: Estudio retrospectivo en pacientes con VIH nTAR valorados en un hospital general de la Ciudad de México de 2009 a 2019. Se recabaron datos antropométricos, clínicos, bioquímicos y relacionados con el estado del VIH. RESULTADOS: Se incluyeron 221 pacientes, el 97% hombres, con mediana de edad 30 años (rango intercuartil [RIC]: 25-38), cuenta de linfocitos CD4 250 células/mm3 (RIC: 120.25-391) y carga viral log10 4.69 copias/ml (RIC: 3.64-5.25) de VIH-1 ARN. La prevalencia de glucosa alterada en ayuno fue del 22.6% y presentó asociación con sobrepeso-obesidad (razón de momios [RM]: 2.75; intervalo de confianza del 95% [IC95%]: 1.36-5.55; p < 0.05). La dislipidemia más frecuente fue la hipoalfalipoproteinemia (69.46%), asociada con CD4 < 250 (RM: 3.23; IC95%: 1.61-6.5; p < 0.05). CONCLUSIONES: Las alteraciones en el metabolismo de los lípidos y de la glucosa son frecuentes entre individuos mexicanos con VIH nTAR; por lo tanto, es importante una adecuada evaluación antes de iniciar el tratamiento.

Beneficio clínico y económico de 32 años de tratamiento antirretroviral de personas que viven con VIH en España: ¿ha sido una intervención eficiente? / Clinical and economic benefit of 32 years of antiretroviral treatment for people living with HIV in Spain: Has it been an efficient intervention?

Introducción: Aunque el tratamiento antirretroviral (TAR) del VIH/sida se introdujo en 1987, la mejora en la progresión de la enfermedad y reducción de la mortalidad poblacional no se observó sino hasta 1996, con la combinación de tres o más fármacos. El objetivo fue estimar el beneficio clínico y económico del TAR en España en el periodo de 32 años, comprendido entre 1987 y 2018. Métodos: Se realizó un análisis de coste-beneficio mediante la simulación de Monte Carlo de segundo orden, desde las perspectivas de la sociedad (caso base) y el Sistema Nacional de Salud (SNS). Los nuevos casos de VIH, sida y muertes relacionadas se obtuvieron de los registros SINIVIH y ONUSIDA, con proyecciones poblacionales sin TAR mediante suavizamiento exponencial triple. El gasto en TAR se obtuvo de informes del Plan Nacional del SIDA y estudios de mercado. Resultados: El SNS invirtió 6.185 millones de euros en 32 años. Durante este periodo se evitaron 323.651 muertes por sida, 500.129 casos de sida y 161.417 casos de VIH, con un ahorro total de 41.997 millones de euros. El beneficio neto (ahorros netos) se estima en 35.812 millones de euros (sociedad) y 1.032 millones de euros (SNS). Por cada euro invertido en TAR, se obtuvo un retorno de la inversión de 6,79 € y 1,16 €, respectivamente. Conclusión: La utilización de TAR durante 32 años ha evitado gran número de muertes y casos de sida y VIH, generando significativos ahorros económicos para el SNS. El TAR es una intervención eficiente para el SNS.(AU)

Introduction: Although antiretroviral therapy (ART) for HIV / AIDS was introduced in 1987, improvement in disease progression and reduction in mortality at a population level was not observed until 1996, with the combination of three or more drugs. The objective was to estimate the clinical and economic benefit of ART in Spain in the 32-year period between 1987 and 2018. Methods: A cost-benefit analysis was performed, using a second-order Monte Carlo simulation, from the societal (base case) and the National Health System (NHS) perspectives. New cases of HIV, AIDS and related deaths were obtained from the SINIVIH and UNAIDS registries, with population projections without ART using triple exponential smoothing. Expenditure on ART was obtained from the National AIDS Plan reports and market studies. Results: The NHS invested 6,185 million euros in 32 years. In that period, 323,651 AIDS-related deaths, 500,129 AIDS cases and 161,417 HIV cases were averted, with total savings of 41,997 million euros. The net benefit (net savings) is estimated at 35,812 million euros (societal) and 1,032 million euros (NHS). For every euro invested in ART, a return on investment of € 6.79 and € 1.16 was obtained, respectively. Conclusion: The use of ART over 32 years prevented a large number of deaths and cases of AIDS and HIV, providing significant economic savings for the NHS. ART is an efficient intervention for the NHS.(AU)

Infección congénita por CMV en recién nacidos hijos de madre con infección por VIH / Congenital cytomegalovirus infection in newborns born to HIV-infected mothers

Introducción: La infección congénita por CMV (CMVc) es más frecuente en hijos expuestos al. VIH durante la gestación, con tasas reportadas en la era pre-TAR del 2 al 7%. El control de la carga viral de VIH y la recuperación inmunológica asociada al tratamiento antirretroviral (TAR) podrían ser factores que influyan en su transmisión. El objetivo de este trabajo fue describir la epidemiología de la infección CMVc en recién nacidos expuestos al VIH en el Hospital Universitario 12 de Octubre, entre los años 2000-2017. Material y métodos: Estudio observacional y retrospectivo. Se recogieron variables epidemiológicas y clínicas a través de la historia clínica de los sujetos incluidos. Se realizó análisis estadístico con el programa informático SPSS 24.0. Resultados: Se incluyeron 288 pares de madres/hijos. Observamos una tasa de CMVc del 2,1% (IC 95% 0,7-4,9). Conclusiones: La tasa de CMVc fue menor a la comunicada en la era pre-TAR, aunque aún parece superior a la observada en niños no expuestos al VIH.(AU)

Introduction: Congenital citomegalovirus (CMVc) infection is more common in children exposed to HIV during pregnancy, with reported rates in pre-ART era from 2 to 7%. The use of combined antiretroviral treatment (ARTc) could be a determining factor in reducing this risk of CMV transmission. The aim of this study was to describe the epidemiology of CMVc infection in newborns of HIV-infected mothers at Hospital Universitario 12 de Octubre, Madrid, Spain, from 2000 to 2017. Material and methods: An observational and retrospective study was carried out. Epidemiological and clinical variables were collected. Statistical analysis was performed with the SPSS 24.0 computer program. Results: 288 mother–infant pairs were included in the study. We observed a CMVc rate of 2.1% (95% CI 0.9–4.9). Conclusions: The rate of CMVc in HIV-exposed children observed was lower than that reported in pre-ARTc era but seems higher than those described in general population.(AU)

Análisis de los costes asociados al seguimiento de pacientes con VIH que discontinúan el tratamiento antirretroviral por falta de eficacia o toxicidad inaceptable en España / Analysis of the costs associated with the follow-up of HIV patients discontinuing antiretroviral treatment due to lack of effectiveness or unacceptable toxicity in Spain

Objetivo: Estimar el uso de recursos y costes asociados al seguimientode pacientes con infección por el virus de la inmunodeficiencia humanatras discontinuación del tratamiento antirretroviral actual debido a faltade efectividad o toxicidad inaceptable y cambio a un nuevo tratamientoantirretroviral, comparado con el seguimiento habitual de los pacientescon tratamiento antirretroviral, desde la perspectiva del Sistema Nacionalde Salud español.Método: Se identificó el uso de recursos (pruebas clínicas, visitasmédicas, visitas a la farmacia hospitalaria) asociado al seguimiento depacientes con infección por el virus de la inmunodeficiencia humana entres perfiles de pacientes (estable, discontinuación y cambio por faltade efectividad, discontinuación y cambio por toxicidad inaceptable), apartir de las guías de práctica clínica y un panel de expertos multidisciplinar (n = 5). Los expertos consensuaron los principales eventos adversos que conducían a la discontinuación, agrupándolos en: alteracionesgastrointestinales, renales, óseas, musculoesqueléticas, dermatológicas,hepáticas y del perfil lipídico, trastornos neuropsiquiátricos y sexuales.Los costes unitarios se identificaron a partir de bases de datos oficiales de costes sanitarios y de la literatura. Se estimó el coste (€, 2020) delseguimiento en cada perfil de paciente, sin incluir el coste derivado deltratamiento antirretroviral, en un horizonte temporal de dos años.Resultados: El coste por paciente a dos años se estimó en 4.148 €(pruebas: 2.293 €; visitas: 1.855 €) para el seguimiento del pacienteestable. (AU)

Objective: To assess the use of resources and the costs associatedwith following up patients infected with the human immunodeficiency virusafter discontinuation of an antiretroviral treatment and initiation of a newone due to a lack of effectiveness or unacceptable toxicity, as comparedto the costs involved in the routine follow-up of patients on antiretroviraltreatment, from the Spanish National Health System perspective.Method: The use of resources (clinical tests, medical visits, and hospitalpharmacy visits) associated with following three profiles of patients infected with the human immunodeficiency virus (stable ones, those discontinuing an existing antiretroviral treatment and being switched to a newone due to a lack of effectiveness, and those discontinuing an existingantiretroviral treatment and being switched to a new one due to unacceptable toxicity) was identified, based on clinical practice guidelinesand the findings of a multidisciplinary expert panel (n = 5). The expertsagreed on the main adverse events leading to discontinuation, classifyingthem into gastrointestinal, renal, osseous, musculoskeletal, dermatological,hepatic, lipid profile-related, neuropsychiatric and sexual alterations. Unitcosts were identified from official healthcare costs databases. The cost (€, 2020) of following up each patient profile was estimated, excludingthe cost of the antiretroviral treatment itself, with a time horizon of twoyears.Results: The per-patient cost of following up stable patients over twoyears was estimated at €4,148 (tests: €2,293; visits: €1,855). Patientfollow-up after discontinuation of an existing antiretroviral treatment andinitiation of a different one due to a lack of effectiveness was estimatedat €5,434 (tests: €2,777; visits: €2,657). (AU)

Congenital cytomegalovirus infection in newborns born to HIV-infected mothers.

INTRODUCTION: Congenital citomegalovirus (CMVc) infection is more common in children exposed to HIV during pregnancy, with reported rates in pre-ART era from 2 to 7%. The use of combined antiretroviral treatment (ARTc) could be a determining factor in reducing this risk of CMV transmission. The aim of this study was to describe the epidemiology of CMVc infection in newborns of HIV-infected mothers at Hospital Universitario 12 de Octubre, Madrid, Spain, from 2000 to 2017. MATERIAL AND METHODS: An observational and retrospective study was carried out. Epidemiological and clinical variables were collected. Statistical analysis was performed with the SPSS 24.0 computer program. RESULTS: 288 mother-infant pairs were included in the study. We observed a CMVc rate of 2.1% (95% CI 0.9-4.9). CONCLUSIONS: The rate of CMVc in HIV-exposed children observed was lower than that reported in pre-ARTc era but seems higher than those described in general population.

Sociodemographic predictors associated with the spectrum of non-opportunist neuroretinal disease of non-infectious etiology in patients with HIV/AIDS: A scoping review.

BACKGROUND: Non-infectious retinal disease, even in the HAART era, continues to be one of the most common diagnoses in patients with HIV, with prevalences of up to 27% of cases. This study aims to characterize the association between demographic variables and their role. As a risk factor for the development of non-opportunistic non-infectious retinal disease in patients with HIV/AIDS. METHODS: An integrative review of the literature was carried out according to Arksey O'Malley's approach, based on the PICO methodology and following the PRISMA recommendations; An exhaustive search was carried out in databases of articles that were filtered using established criteria, with their extraction and analysis carried out qualitatively. RESULTS: Ocular manifestations from any cause develop from 35 years of age in patients with HIV/AIDS, with the highest risk for age-related macular degeneration over the fourth decade of life and for the development of neuroretinal disorder on the fifth decade of life; some studies report a slight tendency to diagnose macular degeneration in women and those who acquired AIDS through sexual contact; data contrasted with increased risk for diagnosing neuroretinal disorder in homosexual men who also use intravenous drugs, possibly due to oversampling in studies; non-Hispanic whites and African Americans were the races most commonly affected by neuroretinal disease; the means between the 11.3-14.5 years elapsed since the HIV diagnosis were more frequently associated with cognitive impairment and both in those with high or low CD4 counts, and in patients with high or low viral loads, neuroretinal disease without Statistically significant differences. Adherence and early initiation of HAART had a modest impact on the development of neuroretinal disease. DISCUSSION: Even in the HAART era, non-infectious neuroretinal disease and cytomegalovirus retinitis remain the most frequent ocular diagnoses, however, different studies argue an increase in age-related non-infectious retinal diseases in patients with HIV, theories that are may explain by the increase in life expectancy, the metabolic effects of HAART itself or the generalized pro-inflammatory state in this group of patients, it is essential to recognize this new diagnostic challenge in order to direct preventive efforts through the use of cost-effective sociodemographic risk predictors towards that technological tools for diagnosis and treatment can be targeted. CONCLUSIONS: HIV/AIDS patients who present at the ophthalmological consultation with the suggested sociodemographic predictors have a high risk of visual impairment due to non-infectious retinopathy, therefore prevention, diagnosis and treatment efforts directed at these diseases should be increased.

Predictores sociodemográficos asociados al espectro de enfermedad neurorretiniana no oportunista de etiología no infecciosa en pacientes con VIH/SIDA: revisión integrativa / Sociodemographic predictors associated with the spectrum of non-opportunist neuroretinal disease of non-infectious etiology in patients with HIV/AIDS: a scoping review

Antecedentes La enfermedad retiniana no infecciosa, aun en la era del tratamiento antirretroviral de gran actividad (TARGA), continúa siendo uno de los diagnósticos más comunes en pacientes con el virus de la inmunodeficiencia humana (VIH), con prevalencias hasta del 27% de los casos. Este estudio se propone caracterizar la asociación entre unas variables demográficas y su papel como factor de riesgo para el desarrollo de la enfermedad retiniana no infecciosa no oportunista en pacientes con VIH/SIDA. Método Se realizó una revisión integrativa de la literatura, según el planteamiento de O’Malley, partiendo de la metodología PICO y siguiendo las recomendaciones elementos de informes preferidos para revisiones sistemáticas y metanálisis (PRISMA); se realizó una búsqueda exhaustiva en bases de datos de artículos que se filtraron mediante criterios establecidos, con la extracción y análisis de los mismos efectuada de forma cualitativa. Resultados Las manifestaciones oculares por cualquier causa se desarrollan desde los 35 años de edad en los pacientes con VIH/SIDA, con el mayor riesgo para la degeneración macular relacionada con la edad sobre la cuarta década de vida y para el desarrollo de trastorno neurorretiniano sobre la quinta; algunos estudios reportan una ligera tendencia para diagnosticar la degeneración macular en mujeres y en aquellas personas que adquirieron SIDA por contacto sexual; estos datos contrastan con un mayor riesgo para diagnosticar el trastorno neurorretiniano en los hombres homosexuales que también usan drogas intravenosas, posiblemente debido un sobremuestreo en los estudios; los blancos no hispánicos y los afroamericanos fueron las razas más comúnmente afectadas por la enfermedad neurorretiniana; las medias entre los 11,3 a 14,5 años transcurridos desde el diagnóstico de VIH se asociaron más frecuentemente con un trastorno cognitivo y tanto en aquellos con recuentos CD4 altos o bajos como en pacientes con cargas (AU)

Background Non-infectious retinal disease, even in the HAART era, continues to be one of the most common diagnoses in patients with HIV, with prevalences of up to 27% of cases. This study aims to characterize the association between demographic variables and their role. as a risk factor for the development of non-opportunistic non-infectious retinal disease in patients with HIV/AIDS Methods An integrative review of the literature was carried out according to Arksey O’Malley's approach, based on the PICO methodology and following the preferred reporting items for systematic reviews and meta-analyses (PRISMA) recommendations; An exhaustive search was carried out in databases of articles that were filtered using established criteria, with their extraction and analysis carried out qualitatively. Results Ocular manifestations from any cause develop from 35 years of age in patients with HIV/AIDS, with the highest risk for age-related macular degeneration over the fourth decade of life and for the development of neuroretinal disorder on the fifth decade of life; some studies report a slight tendency to diagnose macular degeneration in women and those who acquired AIDS through sexual contact; data contrasted with increased risk for diagnosing neuroretinal disorder in homosexual men who also use intravenous drugs, possibly due to oversampling in studies; non-Hispanic whites and African Americans were the races most commonly affected by neuroretinal disease; the means between the 11.3 to 14.5 years elapsed since the HIV diagnosis were more frequently associated with cognitive impairment and both in those with high or low CD4 counts, and in patients with high or low viral loads, neuroretinal disease without Statistically significant differences. Adherence and early initiation of HAART had a modest impact on the development (AU)

Factores asociados al fracaso terapéutico en personas viviendo con VIH con tratamiento antirretroviral: una revisión panorámica de la literatura / Associated factors of treatment failure in people living with HIV taking antiretroviral treatment: a scooping review

Introducción: Se estima que en 2019 vivían 38 millones de personas con el virus de la inmunodeficiencia humana (VIH), para quienes es fundamental el tratamiento antirretroviral (TAR); sin embargo, no siempre funciona. El fracaso terapéutico del TAR sucede cuando existe una progresión de la enfermedad en parámetros clínicos, virológicos o inmunológicos con un peor pronóstico. Objetivo: Identificar los factores asociados al fracaso terapéutico del TAR en personas viviendo con VIH. Métodos: Se siguieron los lineamientos para revisiones sistemáticas de PRISMA-SCR (Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews), modificados por Tricco y otros. Los artículos sobre el fracaso terapéutico en población adulta en primera línea de TAR se hallaron en PubMed y la Biblioteca Virtual de Salud. Información, análisis y síntesis: La definición de fracaso terapéutico utilizada en ocho artículos corresponde con los criterios de la OMS; el resto emplea el criterio virológico con distintos puntos de corte. Se describen factores asociados con el fracaso terapéutico con significación estadística, agrupados en factores sociodemográficos (sexo, edad, edad inicio del TAR, compartir estatus de VIH, empleo de drogas inyectables y nivel educativo) y factores clínicos (niveles de linfocitos T CD4+ al inicio del TAR, nivel de adherencia, cambio de régimen, estadio de la OMS al inicio del TAR y coinfección por tuberculosis). Conclusiones: Dos factores fundamentales en el fracaso terapéutico son los sociodemográficos y los clínicos que dependen de la accesibilidad al tratamiento, el sistema de salud y las características intrínsecas de los individuos, incluyendo las conductas en relación con su enfermedad(AU)

Introduction: It is estimated that by 2019 there are 38 million people living with the human immunodeficiency virus (HIV), for whom antiretroviral treatment is essential. Treatment failure occurs when there is a progression of the disease in clinical, virological, or immunological parameters that lead to a change in treatment and a worse prognosis of the disease. The objective of this panoramic review is to answer the following question: What are the factors associated with the therapeutic failure of antiretroviral treatment in people living with HIV? Methods: A panoramic review was carried out following the guidelines for systematic reviews suggested by PRISMA-SCR (Preferred Reporting Items for Systematic Reviews and Meta-Analyzes extension for Scoping Reviews) and modified by Tricco et al. The articles on therapeutic failure in the adult population on the first line of ART were rescued from PubMed and the Virtual Health Library (VHL). The search was limited to a period from 2010 to 2020 and articles whose population was children or pregnant women and articles not available in English or Spanish were excluded. Information, Analysis and Synthesis: The definition of therapeutic failure used corresponds to the WHO criteria in eight articles, while the rest use the virological criterion in variable reference points. Regarding the factors associated with treatment failure, those with statistical significance grouped into sociodemographic factors (sex, age, age of ART onset, shared HIV status, injection drug use, and educational level) and clinical factors (T CD4+ levels are described at the start of ART, level of adherence, change of regimen, WHO stage at the start of ART, and tuberculosis coinfection). Conclusions: Two fundamental factors in therapeutic failure are sociodemographic and clinical, which in turn depend on accessibility to treatment, the health system and intrinsic characteristics of the individuals and the behaviors they adopt in relation to their disease(AU)

Nutritional status of pediatric patients living with human immunodeficiency virus in Bogotá, Colombia / Nutritional status in children with HIV

Abstract Background: Undernutrition is frequent among children living with HIV in developing countries. An interaction between malnutrition and HIV pediatric infection remains incompletely characterized in Colombia. Methodology: Retrospective longitudinal study, descriptive in nature, in 28 patients with a diagnosis of HIV infection, less than 18 years of age and receiving anti retroviral therapy. Variables were retrieved from clinical records at start of antiretroviral therapy and after 12 months. Statistical analysis was exploratory. Results: 4 out of 28 patients were stunted (14,3%; 95%CI: 1,3 - 27,2), 2 out of 7 patients were wasted (28,6%; 95%CI: 0 - 62), 5 out of 17 patients were underweight (27,8%; 95%CI: 7,1 - 48,5) and 4 out of 28 patients had thinness (29,6%; 95%CI: 12,4 - 46,8). No clinically relevant anthropometric change was detected during follow-up. Anemia prevalence was 52% and 82% of patients had some degree of dyslipidemia. Both viral load (p=0,001) and CD4 count (p=0,01), significantly increased and the proportion of patients with therapeutic failure remained invariable during follow-up. Conclusion: Malnutrition is frequent and its prevalence might have decreased. HIV program improved medical control of the disease, with stable therapeutic failure rates that were comparable with previous reports. Nonetheless, anemia and dyslipidemia remain to be a paramount therapeutic challenge.

Resumen Introducción: La desnutrición es frecuente en niños con VIH en países en desarrollo. En Colombia, la interacción entre la desnutrición y la infección pediátrica por VIH se encuentra insuficientemente caracterizada. Metodología: Estudio longitudinal retrospectivo de carácter descriptivo, en 28 pacientes con diagnóstico de infección por VIH, edad menor a 18 años y con terapia antirretroviral en curso. Se extrajeron variables mediante revisión de historias clínicas en el momento de inicio de la terapia antirretroviral y 12 meses después. El análisis estadístico fue exploratorio. Resultados: 4 de 28 pacientes sufrían retraso del crecimiento (14,3%; IC95%: 1,3 - 27,2), 2 de 7 pacientes sufrían emaciación (28,6%; IC95%: 0 - 62), 5 de 17 pacientes sufrían insuficiencia ponderal (27,8%; IC95%: 7,1 - 48,5) y 4 de 28 pacientes se encontraban en delgadez (29,6%; IC95%: 12,4 - 46,8). No hubo cambios antropométricos clínicamente relevantes con el seguimiento. La prevalencia de anemia fue del 52% y 82% de los pacientes tenían algún grado de dislipidemia. Tanto la carga viral (p=0,001) como el conteo de CD4 (p=0,01), mejoraron significativamente y la proporción de pacientes con fallo terapéutico no cambió durante el seguimiento. Conclusión: La desnutrición es frecuente y su prevalencia podría haber disminuido. El programa de VIH mejoró el control médico de la enfermedad, con tasas de fallo terapéutico estables y comparables con reportes previos. No obstante, la anemia y la dislipidemia continúan siendo un gran reto terapéutico.

Impact of the COVID-19 pandemic: Community and hospital shared pharmaceutical care model. Satisfaction and acceptability of patients with HIV infection on antiretroviral treatment / Impacto de la pandemia COVID-19: Modelo de atención farmacéutica compartida comunitaria y hospitalaria. Satisfacción y aceptabilidad depacientes con infección VIH en tratamiento antirretroviral

Background. The health crisis due to the COVID-19 pandemic is a challenge in the dispensing of outpatient hospital medication (OHM). Models of Antiretroviral Therapy (ART) based on community pharmacy support (ARTCP) have proven to be successful. The aim was to evaluate the degree of satisfaction, acceptability and limitations of the implementation of ARTCP, in the context of a pandemic, in our environment. Methods. Descriptive cross-sectional study carried out in a Barcelona hospital, during the months of July-November 2020. A telephone survey was carried out via a questionnaire on the quality dimensions of the model (degree of satisfaction, acceptability) and associated inconveniences. Data collected: demographics, antiretroviral treatment (ART), concomitant medication, drug interactions (DDIs), CD4 lymphocyte count and plasma viraemia. Data analysis included descriptive statistics. Results. A total of 533 (78.0%) HIV patients receiving ART were included. 71.9% (383/533) of these patients were very satisfied and 76.2% preferred attending the community pharmacy rather than the hospital. The mean satisfaction rating was 9.3 (DS: 1.4). The benefits reported were: 1) proximity to home (406: 76.1%); 2) lower risk of contagion of COVID-19 (318: 59.7%); 3) shorter waiting time (201: 37.1%); 4) time flexibility (104: 19.5%); 5) reduction of financial expenses (35: 6.57%). A total of 11 (2%) patients reported no benefit. Only 22.9% reported disadvantages associated with ARTCP: 1) lack of privacy (65: 12.2%); 2) lack of coordinationorganization (57: 10.7%). Conclusion. The COVID-19 pandemic has had an impact on the provision of pharmaceutical care for HIV patients. The ARTPC model has proved efficient, with patients reporting a high degree of satisfaction. (AU)

Introducción. La crisis sanitaria por la pandemia COVID-19 plantea un desafío en la dispensación de la medicación hospitalaria de dispensación ambulatoria (MHDA). Los modelos de terapia antirretroviral basados en el apoyo de la farmacia comunitaria (TARFC) han demostrado tener éxito. El objetivo del estudio fue evaluar el grado de satisfacción, aceptabilidad y limitaciones de la implementación del TARFC, en contexto de pandemia, en nuestro entorno. Métodos. Estudio descriptivo transversal realizado en un hospital de Barcelona, durante los meses de julio-noviembre del 2020. Se realizó una encuesta telefónica, mediante un cuestionario sobre dimensiones de calidad del modelo (grado de satisfacción, aceptabilidad) e inconvenientes asociados. Se recogieron datos: demográficos, tratamiento antirretroviral (TAR), medicación concomitante, interacciones farmacológicas (DDIs), recuento de linfocitos CD4 y viremia plasmática. El análisis de datos incluyó estadística descriptiva. Resultados. Se incluyeron 533 pacientes VIH adherentes al TAR. El 71,9% (383/533) de pacientes estaban muy satisfechos y el 76,2% preferían acudir a la farmacia comunitaria frente a la hospitalaria. La calificación de satisfacción media fue de 9,3 (DS: 1,4). Los beneficios reportados fueron: 1) cercanía al domicilio (406: 76,1%); 2) menor riesgo de contagio de COVID-19 (318: 59,7%) 3) menor tiempo de espera (201: 37,1%); 4) flexibilidad horaria (104: 19,5%); 5) reducción de gastos económicos (35: 6,57%). Un total de 11 (2%) pacientes no reportaron ningún beneficio. Únicamente el 22,9% reportaron desventajas asociadas al TARFC: 1) falta de privacidad (65:12,2%); 2) falta de coordinación-organización (57: 10,7%) Conclusión. La pandemia de COVID-19 tiene un impacto en la prestación de atención farmacéutica al VIH. El modelo TARFC ha resultado eficiente con un elevado grado de satisfacción por parte de los pacientes. (AU)

Clinical and economic benefit of 32 years of antiretroviral treatment for people living with HIV in Spain: Has it been an efficient intervention?

INTRODUCTION: Although antiretroviral therapy (ART) for HIV/AIDS was introduced in 1987, improvement in disease progression and reduction in mortality at a population level was not observed until 1996, with the combination of three or more drugs. The objective was to estimate the clinical and economic benefit of ART in Spain in the 32-year period between 1987 and 2018. METHODS: A cost-benefit analysis was performed, using a second-order Monte Carlo simulation, from the societal (base case) and the National Health System (NHS) perspectives. New cases of HIV, AIDS and related deaths were obtained from the SINIVIH and UNAIDS registries, with population projections without ART using triple exponential smoothing. Expenditure on ART was obtained from the National AIDS Plan reports and market studies. RESULTS: The NHS invested 6185 million euros in 32 years. In that period, 323,651 AIDS-related deaths, 500,129 AIDS cases and 161,417 HIV cases were averted, with total savings of 41,997 million euros. The net benefit (net savings) is estimated at 35,812 million euros (societal) and 1032 million euros (NHS). For every euro invested in ART, a return on investment of € 6.79 and € 1.16 was obtained, respectively. CONCLUSIONS: The use of ART over 32 years prevented a large number of deaths and cases of AIDS and HIV, providing significant economic savings for the NHS. ART is an efficient intervention for the NHS.

Linfomas asociados a infección por el virus de inmunodeficiencia humana

Objetivos: describir el perfil clínico y resultados del tratamiento de casos de Linfoma asociado a infección por el Virus de Inmunodeficiencia Humana. Métodos: estudio retrospectivo de casos de linfoma asociado a infección por el Virus de Inmunodeficiencia Humana, atendidos en el servicio de Hematología del Hospital Materno Infantil, La Paz, Bolivia durante el periodo 2010-2021. Resultados: se estudiaron ocho casos, de los cuales 6 (75%) eran del sexo masculino. En relación a la edad, la media fue de 40,75 años. 7 (87,5%) eran Linfoma no Hodgkin y un caso a Linfoma de Hodgkin. En siete pacientes el diagnóstico de linfoma fué posterior a la detección de la infección por el Virus de Inmunodeficiencia Humana, con un tiempo medio de 4,6 años. El 75% de los casos se presentaron con un estadio avanzado. De los siete casos de Linfoma no Hodgkin, cinco correspondían al Linfoma Difuso de Células Grandes B. El tratamiento quimioterápico se inició en todos los casos pero solo tres completaron los ciclos programados, el restante dejaron el tratamiento principalmente debido a complicaciones infecciosas. Se registraron cuatro (50%) fallecimientos, de los cuales tres ocurrieron en los primeros cuatro meses desde el diagnóstico de linfoma. Conclusiones: en el presente estudio, el Linfoma no Hodgkin fue el más frecuente, representado principalmente por el Linfoma Difuso de Células Grandes B. Una característica común fue la presentación en estadios avanzados. La quimioterapia no se pudo completar en la mayoría de los casos debido a complicaciones relacionadas con la inmunodepresión, la mitad de los casos fallecieron durante el periodo de estudio.

Objectives: to describe the clinical profile and treatment outcomes of cases of lymphoma associated with Human Immunodeficiency Virus infection. Methods: retrospective study of cases of lymphoma associated with Human Immunodeficiency Virus infection treated at the Hematology Department of the Materno Infantil Hospital, La Paz, Bolivia during the period 2010-2021. Results: Eight cases were studied, of which 6 (75%) were male. The mean age was 40.75 years. 7 (87.5%) were Non-Hodgkin's Lymphoma and one case was Hodgkin's Lymphoma. In seven patients, the diagnosis of lymphoma was made after the detection of Human Immunodeficiency Virus infection, with a mean time of 4.6 years. 75% of the cases presented with advanced stage. Of the seven cases of Non-Hodgkin's Lymphoma, five corresponded to Large B-Cell Lymphoma. Chemotherapy was started in all cases but only three completed the scheduled cycles, the remainder stopped treatment mainly due to infectious complications. Four (50%) deaths were recorded, three of which occurred within the first four months after the diagnosis of lymphoma. Conclusions: In this study, Non-Hodgkin's Lymphoma was the most frequent, represented mainly by Large B-Cell Lymphoma. A common characteristic was the presentation at advanced stages. Chemotherapy could not be completed in the majority of cases due to complications related to immunodepression, and half of the cases died during the study period.

Clinical and economic benefit of 32 years of antiretroviral treatment for people living with HIV in Spain: Has it been an efficient intervention? / Beneficio clínico y económico de 32 años de tratamiento antirretroviral de personas que viven con VIH en España: ¿ha sido una intervención eficiente?

INTRODUCTION: Although antiretroviral therapy (ART) for HIV / AIDS was introduced in 1987, improvement in disease progression and reduction in mortality at a population level was not observed until 1996, with the combination of three or more drugs. The objective was to estimate the clinical and economic benefit of ART in Spain in the 32-year period between 1987 and 2018. METHODS: A cost-benefit analysis was performed, using a second-order Monte Carlo simulation, from the societal (base case) and the National Health System (NHS) perspectives. New cases of HIV, AIDS and related deaths were obtained from the SINIVIH and UNAIDS registries, with population projections without ART using triple exponential smoothing. Expenditure on ART was obtained from the National AIDS Plan reports and market studies. RESULTS: The NHS invested 6,185 million euros in 32 years. In that period, 323,651 AIDS-related deaths, 500,129 AIDS cases and 161,417 HIV cases were averted, with total savings of 41,997 million euros. The net benefit (net savings) is estimated at 35,812 million euros (societal) and 1,032 million euros (NHS). For every euro invested in ART, a return on investment of € 6.79 and € 1.16 was obtained, respectively. CONCLUSION: The use of ART over 32 years prevented a large number of deaths and cases of AIDS and HIV, providing significant economic savings for the NHS. ART is an efficient intervention for the NHS.

Sociodemographic predictors associated with the spectrum of non-opportunist neuroretinal disease of non-infectious etiology in patients with HIV/AIDS: a scoping review. / Predictores sociodemográficos asociados al espectro de enfermedad neurorretiniana no oportunista de etiología no infecciosa en pacientes con VIH/SIDA: revisión integrativa.

BACKGROUND: Non-infectious retinal disease, even in the HAART era, continues to be one of the most common diagnoses in patients with HIV, with prevalences of up to 27% of cases. This study aims to characterize the association between demographic variables and their role. as a risk factor for the development of non-opportunistic non-infectious retinal disease in patients with HIV/AIDS METHODS: An integrative review of the literature was carried out according to Arksey O'Malley's approach, based on the PICO methodology and following the preferred reporting items for systematic reviews and meta-analyses (PRISMA) recommendations; An exhaustive search was carried out in databases of articles that were filtered using established criteria, with their extraction and analysis carried out qualitatively. RESULTS: Ocular manifestations from any cause develop from 35 years of age in patients with HIV/AIDS, with the highest risk for age-related macular degeneration over the fourth decade of life and for the development of neuroretinal disorder on the fifth decade of life; some studies report a slight tendency to diagnose macular degeneration in women and those who acquired AIDS through sexual contact; data contrasted with increased risk for diagnosing neuroretinal disorder in homosexual men who also use intravenous drugs, possibly due to oversampling in studies; non-Hispanic whites and African Americans were the races most commonly affected by neuroretinal disease; the means between the 11.3 to 14.5 years elapsed since the HIV diagnosis were more frequently associated with cognitive impairment and both in those with high or low CD4 counts, and in patients with high or low viral loads, neuroretinal disease without Statistically significant differences. Adherence and early initiation of HAART had a modest impact on the development of neuroretinal disease. DISCUSSION: Even in the HAART era, non-infectious neuroretinal disease and cytomegalovirus retinitis remain the most frequent ocular diagnoses, however, different studies argue an increase in age-related non-infectious retinal diseases in patients with HIV, theories that are may explain by the increase in life expectancy, the metabolic effects of HAART itself or the generalized pro-inflammatory state in this group of patients, it is essential to recognize this new diagnostic challenge in order to direct preventive efforts through the use of cost-effective sociodemographic risk predictors towards that technological tools for diagnosis and treatment can be targeted. CONCLUSIONS: HIV/AIDS patients who present at the ophthalmological consultation with the suggested sociodemographic predictors have a high risk of visual impairment due to non-infectious retinopathy, therefore prevention, diagnosis and treatment efforts directed at these diseases should be increased.

Maternidade e HIV: continuidade do tratamento e adesão em mulheres após parto / Motherhood and HIV: retention in HIV care and adherence in postpartum women / Maternidad y VIH: continuidad del tratamiento y adherencia en mujeres en el posparto

O estudo examinou fatores sociodemográficos, clínicos e psicossociais que afetam a continuidade do tratamento e a adesão à medicação antirretroviral em mulheres nos primeiros três meses após o parto. Participaram 56 mulheres vivendo com HIV, com idades entre 18 e 43 anos, na sua grande maioria brancas e casadas. Foram utilizadas entrevistas sobre dados sociodemográficos e clínicos, exames laboratoriais e escalas psicológicas. Análises estatísticas revelaram que mais de um terço das participantes (37,5%) descontinuaram o próprio tratamento após o parto. A qualidade de vida e o apoio instrumental podem favorecer a continuidade do tratamento de HIV após o parto, e as condições de trabalho e a situação clínica dessas mulheres pode afetar a adesão após o parto. Tais resultados podem contribuir para o desenvolvimento de intervenções que favoreçam a continuidade do tratamento e adesão das mulheres no pós-parto. (AU)

This study examined sociodemographic, clinical, and psychosocial factors affecting retention in HIV care and antiretroviral adherence in women during the first three months after delivery. Participants were 56 women living with HIV, aged between 18 and 43 years, mostly white and married. We used interviews about socio-demographic and clinical data, laboratory tests, and psychological scales. Statistical analyses revealed that more than one-third of women (37.5%) discontinued their treatment after delivery. Quality of life and instrumental support may contribute to retention in HIV care after childbirth, and the working conditions and clinical status of these women may affect adherence after childbirth. These findings may contribute to the development of interventions that promote retention in HIV care and adherence during the postpartum period. (AU)

Este estudio examinó los aspectos sociodemográficos, clínicos y psicosociales que afectan la continuidad del tratamiento del VIH y adherencia a los antirretrovirales en las mujeres en los tres meses después del parto. Participaron 56 madres infectadas por VIH, con edades comprendidas entre 18 y 43 años. La mayoría eran blancas y estaban casadas. Se utilizaron entrevistas sobre datos sociodemográficos y clínicos, exámenes de laboratorio y escalas psicológicas. Los análisis estadísticos revelaron que más de un tercio de las mujeres (37,5%) interrumpieron su tratamiento después del parto. La calidad de vida y el apoyo instrumental pueden favorecer la continuidad del tratamiento del VIH después del parto, y que las condiciones laborales y la situación clínica de estas mujeres pueden afectar la adherencia después del parto. Estos resultados pueden contribuir al desarrollo de intervenciones para favorecer la continuidad del tratamiento y la adherencia de las mujeres en el posparto. (AU)

Consenso de la infección por VIH en embarazadas, niños, adolescentes

La infección por VIH sigue impactando de manera significativa a embarazadas, niños y adolescentes. En las embarazadas, es necesario hacer la prueba de VIH en la primera consulta prenatal o al primer contacto con el sistema de salud, y luego repetir en el tercer trimestre, preferiblemente antes de las 36 semanas de gestación, en caso de que el resultado sea negativo inicialmente; mientras que el diagnóstico en pediatría se basa en la realización de pruebas virológicas (PCR DNA o RNA) en niños menores de 18 meses y de pruebas serológicas en mayores de 18 meses, con seguimientos periódicos a fin de evaluar la evolución clínica, adherencia y posible toxicidad medicamentosa. En ambas poblaciones, es necesario considerar, previo al inicio del TARV la realización del test de resistencia a fin de orientar la terapéutica, con posteriores controles de carga viral plasmática (CVP) y contaje de linfocitos T CD4. La utilización del TARV implica resaltar un objetivo epidemiológico, pues su uso se asocia con riesgo menor de transmisión maternoinfantil. En este consenso se busca disponer de recomendaciones en relación con el diagnóstico y TARV de embarazadas, niños y adolescentes con infección por VIH, las cuales puedan servir de orientación al clínico especialista en el área, dada la complejidad y avances constantes en la investigación de las distintas familias de antirretrovirales, así como su eficacia, toxicidad, interacciones medicamentosas, aparición de resistencias, tropismo y al adecuado manejo en diversas situaciones especiales.

HIV infection continues to significantly impact pregnant women, children and adolescents. In pregnant women, it is necessary to do the HIV test at the first prenatal visit or at the first contact with the health system, and then repeat in the third trimester, preferably before 36 weeks of gestation, in case the result is negative. initially; while the diagnosis in pediatrics is based on the performance of virological tests (DNA or RNA PCR) in children younger than 18 months and serological tests in those older than 18 months, with periodic follow-ups in order to evaluate the clinical evolution, adherence and possible drug toxicity. In both populations, it is necessary to consider, prior to the start of ART, the performance of the resistance test in order to guide therapy, with subsequent controls of plasma viral load (CVP) and CD4 T lymphocyte count. The use of ART implies highlighting an epidemiological objective, since its use is associated with a lower risk of mother-to-child transmission. This consensus seeks to have recommendations in relation to the diagnosis and ART of pregnant women, children and adolescents with HIV infection, which can serve as guidance to the clinical specialist in the area, given the complexity and constant advances in the investigation of the different families of antiretrovirals, as well as their efficacy, toxicity, drug interactions, emergence of resistance, tropism and proper management in various special situations.